Готові списки джерел за темами / Non-steroidal anti-inflammatory Drug (NSAID)

Добірка наукової літератури з теми "Non-steroidal anti-inflammatory Drug (NSAID)"

Автор: Grafiati
Опубліковано: 7 вересня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Зміст

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Non-steroidal anti-inflammatory Drug (NSAID)".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Non-steroidal anti-inflammatory Drug (NSAID)"

1

Ismatov, Farrukh Asliddinovich. "DRUG TREATMENT WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS JAW ALVEOLITIS." Frontline Medical Sciences and Pharmaceutical Journal 02, no. 03 (March 1, 2022): 88–94. http://dx.doi.org/10.37547/medical-fmspj-02-03-09.

Повний текст джерела
Анотація:
Non-steroidal anti-inflammatory drugs are widely used to suppress inflammation in the body. NSAIDs are available in different forms: tablets, capsules, ointments. They have three main properties: antipyretic, anti-inflammatory and analgesic. The best non-steroidal anti-inflammatory drug can only be chosen by a doctor, based on the individual characteristics of the patient. Self-treatment in this case may be fraught with serious adverse reactions or overdose. We suggest reading the list of drugs. The rating is based on value for money, patient feedback and expert opinion.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Karadurmus, Leyla, I. Firat Sahin, Sevinc Kurbanoglu, and Sibel A. Ozkan. "Electrochemical Determination of Non-Steroidal Anti-Inflammatory Drugs." Current Analytical Chemistry 15, no. 4 (July 3, 2019): 485–501. http://dx.doi.org/10.2174/1573411014666180917113920.

Повний текст джерела
Анотація:
Electrochemical methods have been used for the determination of nonsteroidal antiinflammatory drugs (NSAID) just as used in the determination of various drugs. Among voltammetric methods; differential pulse voltammetric method, square wave voltammetric method and linear sweep voltammetric method are the most commonly used ones. NSAIDs are widely used in the treatment of inflammatory conditions such as musculoskeletal disorders (rheumatoid arthritis, osteoarthritis, acute gouty arthritis) and dental pain, menstrual pain, postoperative pain and migraine. In this review, some selected recent electrochemical studies were selected related to the nonsteroidal antiinflammatory drug analyzes. The aim of this review is to evaluate and discuss the advantages, details and usages of electroanalytical methods in the determination of nonsteroidal anti-inflammatory drug.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Bangerl, Teresa, Brigitte Zahel, Andrea Lueger, Emmanuella Guenova, Irena Angelova-Fischer, and Wolfram Hoetzenecker. "Hypersensitivity reactions to non-steroidal anti-inflammatory drugs: results of an Austrian cohort study." Allergo Journal International 29, no. 7 (July 14, 2020): 227–32. http://dx.doi.org/10.1007/s40629-020-00134-6.

Повний текст джерела
Анотація:
Summary Background Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) is the second most common cause of drug hypersensitivity. Despite the importance of NSAIDs in routine analgesia only few studies have systematically addressed the question of tolerability in hypersensitive patients. Methods The authors retrospectively analysed 398 patients that were treated at the Department of Dermatology, Kepler University Hospital Linz, Austria, in the period 2012–2016 with a clinical history of NSAID hypersensitivity. Skin tests (skin prick and intracutaneous tests) to common NSAIDs were performed, followed by single-blinded, placebo-controlled drug challenge with either the culprit drug or an alternative NSAID. Results A total of 361 patients were subjected to skin testing. Of these, 25 patients (6.3%) showed a positive reaction to the culprit drug. According to the severity of the reaction in the medical history, 87 patients were exposed orally to the culprit drug (oral provocation test, OPT) after negative skin test and 255 patients received OPT with alternative NSAIDs according to established protocols. OPT with the culprit drug resulted in hypersensitivity reactions in 12 patients (13.79%). In terms of alternative NSAID testing, the three most commonly tested drugs were lornoxicam (192 OPTs), acetaminophen (156 OPTs) and celecoxib (133 OPTs) with tolerability rates in respectively 88.54% (hypersensitivity reactions, 11.46%), 92.31% (hypersensitivity reactions, 7.69%) and 91.73% (hypersensitivity reactions, 8.27%) of cases. Conclusion OPT with alternative NSAIDs are useful in patients with NSAID hypersensitivity as tolerability varies between the individual substances.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Tachecí, Ilja, Marcela Kopáčová, Stanislav Rejchrt, and Jan Bureš. "Non-steroidal Anti-inflammatory Drug Induced Injury to the Small Intestine." Acta Medica (Hradec Kralove, Czech Republic) 53, no. 1 (2010): 3–11. http://dx.doi.org/10.14712/18059694.2016.56.

Повний текст джерела
Анотація:
Non-steroidal anti-inflammatory drug (NSAIDs) induced enteropathy represents an important complication of one of the most commonly used drugs worldwide. Due to previous diagnostics difficulties the real prevalence of this disease was underestimated for a long time. The pathogenesis of NSAID-enteropathy is more multifactorial and complex than formerly assumed but has still not been fully uncovered. A combination of the local and systemic effect plays an important role in pathogenesis. Thanks to novel enteroscopy methods (wireless capsule endoscopy, double balloon enteroscopy), small bowel lesions are described in a substantial section of NSAID users although most are clinically asymptomatic. The other non-invasive tests (small bowel permeability, faecal calprotectin, scintigraphy using faecal excretion of 111-indium-labelled leukocytes etc.) proposed for diagnostics are not generally used in clinical practice, mainly because of their non-specificity. Despite intensive research into possible treatment, the main measure for patients with NSAID-enteropathy is still withdrawal of NSAIDs. Double balloon enteroscopy plays an important role in the treatment of complications (bleeding, strictures).
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Vasilyuk, V. B., G. I. Syraeva, and M. V. Faraponova. "Efficacy and safety of non-steroidal anti-inflammatory drugs for acute attack of gout." Russian Medical Inquiry 5, no. 2 (2021): 96–101. http://dx.doi.org/10.32364/2587-6821-2021-5-2-96-101.

Повний текст джерела
Анотація:
Gout is one of the most common forms of inflammatory arthritis. Medical care for gout includes non-steroidal anti-inflammatory drugs (NSAIDs). This paper reviews the efficacy and safety of NSAIDs prescribed for the acute attack of gout, in particular, AMBENIUM® parenteral. It was demonstrated that phenylbutazone is a powerful NSAID that provides significant analgesic and anti-inflammatory effects. Considering a broad spectrum of adverse reactions of NSAIDs, these agents should be prescribed and used under in-depth analysis of patient’s condition, comorbidities and the level of their decompensation, and potential drug interactions. In addition, optimal dosages and duration of NSAID treatment are of particular importance. The authors conclude that AMBENIUM® parenteral is an effective and safe therapeutic modality for gout. Its profile and risk/benefit ratio are regarded as “favorable” compared to other NSAIDs. KEYWORDS: gout, arthritis, pain, non-steroidal anti-inflammatory drugs, parenteral, efficacy, safety. FOR CITATION: Vasilyuk V.B., Syraeva G.I., Faraponova M.V. Efficacy and safety of non-steroidal anti-inflammatory drugs for acute attack of gout. Russian Medical Inquiry. 2021;5(2):96–101. DOI: 10.32364/2587-6821-2021-5-2-96-101.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Jang, Soo Min, Ruixin Jiang, Darren Grabe, and Amy Barton Pai. "Assessment of literacy and numeracy skills related to non-steroidal anti-inflammatory drug labels." SAGE Open Medicine 7 (January 2019): 205031211983411. http://dx.doi.org/10.1177/2050312119834119.

Повний текст джерела
Анотація:
Background: Non-steroidal anti-inflammatory drugs are widely used and have a potential for over-the-counter misuse. Limited health literacy is associated with poor health outcomes. Identification of new strategies to assess literacy and numeracy could be useful in targeting effective education initiatives. Objective: To characterize numeracy and literacy skills related to non-steroidal anti-inflammatory drug labels in primary care patients. Methods: Patients were recruited and consented over an 8-month period after their regular primary care visit. Demographic information was collected and two instruments were administered to assess literacy and numeracy skills: (1) a medication label literacy instrument focused on non-steroidal anti-inflammatory drugs (MedLit-NSAID) and (2) a general healthy literacy-screening tool, the Newest Vital Sign. Two questions on the MedLit-NSAID instrument evaluated understanding of the Food and Drug Administration medication guide for non-steroidal anti-inflammatory drugs and the Food and Drug Administration approved over-the-counter label. Results: A total of 145 patients were enrolled. Mean MedLit-NSAID and Newest Vital Sign scores were 6.8 (scale range 0–8) and 4.2 (scale range 0–6), respectively. Higher education level was associated with higher scores for both tools (p ⩽ 0.05). Total MedLit-NSAID scores on average were higher in females compared with males (6.5 vs 6, p = 0.05). Patients with decreased kidney function (n = 18) had significantly lower MedLit-NSAID scores (p ⩽ 0.05). Test–retest scores were not significantly different for MedLit-NSAID (p = 0.32). The correlation between the tools was 0.54 and internal consistency MedLit-NSAID was 0.61. Conclusion: A medication information focused instrument provided specific information to assess health literacy related to non-steroidal anti-inflammatory drug labels. This information could be utilized to develop patient education initiatives for medication label comprehension.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Miranda, Gustavo Marinho, Vitória Ohana Ramos e. Santos, Jonatas Reis Bessa, Yanna C. F. Teles, Setondji Cocou Modeste Alexandre Yahouédéhou, Marilda Souza Goncalves, and Jaime Ribeiro-Filho. "Inclusion Complexes of Non-Steroidal Anti-Inflammatory Drugs with Cyclodextrins: A Systematic Review." Biomolecules 11, no. 3 (February 27, 2021): 361. http://dx.doi.org/10.3390/biom11030361.

Повний текст джерела
Анотація:
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most widely used classes of medicines in the treatment of inflammation, fever, and pain. However, evidence has demonstrated that these drugs can induce significant toxicity. In the search for innovative strategies to overcome NSAID-related problems, the incorporation of drugs into cyclodextrins (CDs) has demonstrated promising results. This study aims to review the impact of cyclodextrin incorporation on the biopharmaceutical and pharmacological properties of non-steroidal anti-inflammatory drugs. A systematic search for papers published between 2010 and 2020 was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol and the following search terms: “Complexation”; AND “Cyclodextrin”; AND “non-steroidal anti-inflammatory drug”. A total of 24 different NSAIDs, 12 types of CDs, and 60 distinct inclusion complexes were identified, with meloxicam and β-CD appearing in most studies. The results of the present review suggest that CDs are drug delivery systems capable of improving the pharmacological and biopharmaceutical properties of non-steroidal anti-inflammatory drugs.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Flood, Jordan, and Allison Stewart. "Non-Steroidal Anti-Inflammatory Drugs and Associated Toxicities in Horses." Animals 12, no. 21 (October 26, 2022): 2939. http://dx.doi.org/10.3390/ani12212939.

Повний текст джерела
Анотація:
Effective pain management in horses can be a challenge despite the understanding that appropriate analgesia improves animal welfare and increases treatment success. The administration of NSAID drugs, particularly phenylbutazone and flunixin, are common practice in equine veterinary patients. Known for their analgesic and anti-inflammatory properties, NSAIDs are used for the treatment of a variety of conditions in horses, from gastrointestinal to orthopedic pain. Despite extensive usage, NSAIDs have a narrow margin of safety and the body of literature documenting the efficacy and side effects of different NSAIDs is broad. The three main side effects associated with excessive or prolonged NSAID usage in horses include gastroduodenal ulceration, right dorsal colitis (RDC) and renal papillary necrosis. The use of cyclooxygenase-2 selective NSAIDS, such as firocoxib, are theoretically safer. The aim of this paper is to review the current literature on the use and efficacy of different NSAIDs, summarise the associated side effects of NSAID usage and evaluate the current state of knowledge for the diagnosis and treatment of such toxicities.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Levantino, Laura, Cristiana Corrado, Laura Badina, Sara Lega, and Egidio Barbi. "Ipersensibilità ai FANS: intolleranza o allergia?" Medico e Bambino 40, no. 1 (January 28, 2021): 37–43. http://dx.doi.org/10.53126/meb40037.

Повний текст джерела
Анотація:
Non-steroidal anti-inflammatory drugs (NSAIDs) are the main triggers of drug hypersensitivity reactions in children. According to the EAACI latest classification NSAIDs hypersensitivity reactions are differentiated into cross-reactive reactions, with non-immunological mechanisms (based on COX-1 inhibition), and selective reactions, with immunological mechanisms. Paediatric clinical manifestations of NSAID hypersensitivity are typically cutaneous, but sometimes, similarly to anaphylaxis, can involve other systems, especially the respiratory one. Differentiating between NSAID intolerance and NSAID allergy through drug provocation tests is crucial for the patient because the two clinical entities require different management.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

McDonald, Janet, Lynn McBain, Anthony C. Dowell, and Caroline Morris. "GPs’ views and experiences of prescribing non-steroidal anti-inflammatory drugs: a qualitative study." BJGP Open 1, no. 2 (May 30, 2017): bjgpopen17X100869. http://dx.doi.org/10.3399/bjgpopen17x100869.

Повний текст джерела
Анотація:
BackgroundNon-steroidal anti-inflammatory drugs (NSAIDs) are widely prescribed in primary care despite being a high-risk drug group causing significant adverse events, yet little is known about GPs’ perceptions of NSAID risks and benefits.AimTo explore GPs’ experiences with NSAID prescribing and views about the risks and benefits of this group of medicines.Design & settingA qualitative, inductive study in general practice.MethodIndividual interviews with 15 GPs using a semi-structured interview guide. Interviews were audiorecorded and transcribed. An inductive, thematic approach was used for analysis. Sampling continued until data saturation was achieved.ResultsThree main themes illustrate GPs’ key concerns with managing NSAID risks. The first theme was perceptions of risks and benefits of NSAIDs: GPs expressed differing attitudes towards prescribing medication generally. GPs were aware of the general risks of NSAIDs but weighed these up against specific risk factors and potential benefits for particular patients. They were most concerned about long-term use, risks for children, older people, and patients with comorbidities. The second theme was assessing and mitigating risks when prescribing NSAIDs: GPs considered gastric, cardiac, and renal risks of patients as well as drug interactions. Mitigation strategies included alternative treatment, choice and dose of NSAID, and use of gastroprotective agents. The final theme was other factors impacting on NSAID risks: particularly patient expectations and over-the-counter (OTC) availability.ConclusionNSAID prescribing is a complex balance between pragmatism and potential adverse events. Given the costs of morbidity, hospitalisation, and patient demand there is an urgent need to secure a more detailed evidence base and develop practical pathways to support safer prescribing.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "Non-steroidal anti-inflammatory Drug (NSAID)"

1

Padayachee, Vaneshree. "Awareness regarding non-steroidal anti-inflammatory drug-related side effects in Johannesburg, South Africa." University of Western Cape, 2021. http://hdl.handle.net/11394/8370.

Повний текст джерела
Анотація:
>Magister Scientiae - MSc
Non-steroidal anti-inflammatory drugs (NSAIDs) are amongst the most commonly used medications globally, as they are highly effective and easily accessible. The NSAIDs are indicated for mild to moderate pain management. The increasing incidence of NSAID related side effects and hospitalisations has raised a concern about these medications’ safety. The prevalence of these side effects has drastic consequences to a challenged South Africanpublic healthcare system. The implications of not treating severe, potentially preventable upper gastrointestinal complications attributed to NSAIDs’ consumption continue to be a significant problem that healthcare professionals (HCP) face.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Sigthorsson, Gudmundur. "Studies into the pathogenic mechanism of NSAID-enteropathy." Thesis, King's College London (University of London), 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.272070.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Barton, Garry Richard. "Economic aspects of NSAID (non-steroidal anti-inflammatory drug) provision : use, benefits and optimal decisions." Thesis, University of Nottingham, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.444633.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Sasane, Rahul Madhukar. "Assessment of the effectiveness of a non-steroidal anti-inflammatory drug (NSAID) algorithm in an integrated healthcare system /." Digital version accessible at:, 1998. http://wwwlib.umi.com/cr/utexas/main.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Morales, Daniel. "Quantifying the risk of beta-blockers and non-steroidal anti-inflammatory drugs in asthma." Thesis, University of Dundee, 2014. https://discovery.dundee.ac.uk/en/studentTheses/56ca8828-73f6-47cc-b919-6e3e78e11a7b.

Повний текст джерела
Анотація:
Beta-blockers and non-steroidal anti-inflammatory drugs (NSAIDs) are often avoided in asthma over risk of bronchospasm which may vary according to drug selectivity and duration of administration. This thesis attempts to quantify the risk of beta-blocker and NSAID exposure in asthma by synthesising clinical trial evidence and conducting observational studies using linked electronic medical records. As part of this thesis, three systematic reviews of clinical trials were conducted evaluating: the prevalence of aspirin-exacerbated respiratory disease (AERD); risk of selective NSAIDs/COX-2 inhibitors in people with AERD; and risk of acute beta-blocker exposure in people with asthma. Electronic primary care data from the Clinical Practice Research Datalink (CPRD) was used to define a cohort of people with active asthma, measure the prevalence of beta-blocker and NSAID prescribing, and perform a series of nested case control studies evaluating asthma death, asthma hospitalisation and primary care asthma exacerbations (PCAE). A self-controlled case-series was performed for PCAE as well. Based upon work in this thesis, the prevalence of AERD in people with asthma was around 9%. Selective NSAIDs triggered respiratory symptoms in 8% of people with AERD whilst no significant changes in lung function or symptoms occurred with COX-2 inhibitors. Acute non-selective beta-blocker exposure caused a significant mean fall in FEV1 of 10%, a significant increase in respiratory symptoms in around 1 in 13 and a non-significant increase in falls in FEV1 of ≥20% in around 1 in 9. Acute selective beta-blocker exposure caused a significant mean fall in FEV1 of 7%, significant falls in FEV1 of ≥20% in around 1 in 8 and a non-significant increase in respiratory symptoms in around 1 in 33. The prevalence of selective beta-blocker prescribing in asthma rose by around 200% over the 12 year period whilst the prevalence of non-selective beta-blocker prescribing rose by around 90%. Changing trends in NSAID prescribing occurred over the 12 year period with COX-2 inhibitors now rarely prescribed. Using the nested case control design, both incident and high-dose non-selective beta-blocker exposure was associated with significantly increased risk of asthma morbidity (hospitalisation and PCAE). In contrast, no significant increased risk of asthma morbidity occurred with any type of selective beta-blocker exposure. Consistent findings were seen for PCAE using the self-controlled case series. No significantly increased risk was seen with different oral NSAIDs apart from weak evidence of an association between asthma death and non-selective NSAID exposure which is unlikely to be causal. Significant numbers of people with asthma are prescribed beta-blockers and NSAIDs. Evidence from clinical trials and observational studies demonstrate that non-selective beta-blockers significantly increase asthma morbidity with risk appearing to vary according to dose and duration of administration. Although selective beta-blockers have the potential to cause significant changes in lung function, no significant increase in asthma morbidity was observed in observational studies. Although around 9% of asthmatics may be susceptible to NSAIDs, no strong evidence was found to suggest that the current practice of NSAID prescribing increases asthma morbidity. At the same time, COX-2 inhibitors are infrequently prescribed despite apparently being well tolerated by people with AERD.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Rafi, Shegufta Susan. "Studies on the pathogenesis of NSAID-induced damage to the gastrointestinal tract with special reference to the mitochondria." Thesis, King's College London (University of London), 1998. https://kclpure.kcl.ac.uk/portal/en/theses/studies-on-the-pathogenesis-of-nsaidinduced-damage-to-the-gastrointestinal-tract-with-special-reference-to-the-mitochondria(10f8f528-5777-4452-9706-359076c35bca).html.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Jacob, Molly. "Mechanism of non-steroidal anti-inflammatory drug induced damage in the small bowel." Thesis, King's College London (University of London), 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.313890.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Buckley, Trevor R. "Does Non-Steroidal Anti-Inflammatory Drug (NSAID) Use Affect Dementia Progression and Survival Rates in Alzheimer's Disease? The Cache County Study." DigitalCommons@USU, 2011. https://digitalcommons.usu.edu/etd/990.

Повний текст джерела
Анотація:
Alzheimer's disease (AD) has multiple factors that contribute to the disease process. Among these is a state of chronic inflammation that is endured by the brain during the aging process. The use of non-steroidal anti-inflammatory drugs (NSAIDs) decreases the amount of neuroinflammation sustained by the brain, and greater levels of NSAID use have been demonstrated to be associated with decreased probability of developing AD. This study looked at whether greater rates of NSAID use were also associated with decreased rates of cognitive and funtional decline and survival in a population-based sample of persons with AD.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Pangburn, Heather Ann. "Effects of the non-steroidal anti-inflammatory drug (NSAID) sulindac on epidermal growth factor receptor (EGFR) expression and signaling in colorectal cancer /." Connect to full text via ProQuest. Limited to UCD Anschutz Medical Campus, 2007.

Знайти повний текст джерела
Анотація:
Thesis (Ph.D. in Toxicology) -- University of Colorado Denver, 2007.
Typescript. Includes bibliographical references (leaves 156-176). Free to UCD affiliates. Online version available via ProQuest Digital Dissertations;
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Harmzen, Magdalena Adriana. "Overview of the prescribing patterns of non-steroidal anti-inflammatory drugs : 2004-2006 / Magdalena Adriana Harmzen." Thesis, North-West University, 2008. http://hdl.handle.net/10394/3719.

Повний текст джерела
Анотація:
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for systemic control of acute and chronic pain and inflammation (Lin et ah, 2000:1129), but usage problems and side-effects that occur during the post-marketing phase of these drugs are well documented (Thiefin & Beaugerie, 2005:287). Following the demonstration of the value of anti-inflammatory therapy in diseases like rheumatoid arthritis (Boardman & Dudley Hart, 1967:268), new NSAIDs appeared on the market (Dieppe et al., 2004:867), and the indications steadily broadened from inflammatory diseases to almost any painful condition. Studies have indicated that NSAID-associated serious upper gastro-intestinal (GI) adverse events result in 103 000 hospitalisations (Bombardier, 2002:4) and 165 000 deaths per year in the United States. A study in South Africa in 2002 indicated that NSAID utilisation contributed considerably to the total cost of all medicine items from a medicine claim database in the private health care sector (Joubert, 2002:260). The objective of this study was to determine the prevalence and cost of non-steroid anti-inflammatory drugs in a section of the private health care sector, and specifically to determine the prevalence, usage and cost of Coxib (Specific cyclo-oxygenase-2 inhibitor) medicine items before and after the withdrawal of Vioxx® from the market in September 2004 (Merck, 2004). Data from two medicine claim databases for the years 2004, 2005 and 2006 (medicine claim database I) and the years 2005 and 2006 (medicine claim database M), were analysed by means of a retrospective drug utilisation review (DUR) study. The usage of Coxib medicine items was determined, and compared for the periods before and after the withdrawal of Vioxx® in September 2004. It was found that between 9 and 10.5 per cent of prescriptions dispensed through both medicine claim database I and medicine claim database M during the study period were NSAID prescriptions. NSAID medicine items on medicine claim database I represented between 3.9 % (R25 942 986) and 2.9 % (R8 073 034) of the total cost of all medicine items claimed from 2004 to 2006. NSAIDs represented 3.1 % (R58 290 412) and 2.8 % (R57 752 267) of the cost of all medicine items claimed through medicine claim database M during 2005 and 2006 respectively, indicating similar trends in the two medicine claim databases. The prevalence of Coxibs on medicine claim database I decreased from almost 20 % (47 938) in 2004 to 8.4 % (13 276) in 2005, but showed an increase again to 10.9 % (12 355) in 2006. The prevalence of both cyclo-oxygenase (COX) inhibitors, and Coxibs demonstrated a change during 1 September 2004 to 31 December 2004 when COX-inhibitors showed an increase in use, while Coxibs showed and almost equal but opposite trend with a decrease in use. This could possibly be related to perceptions of providers and public with regard to Coxibs and their related safety after the withdrawal of Vioxx® on 30 September 2004 (Merck, 2004) and other Coxibs such as Bextra® (FDA, 2005) in 2005 in USA. It is concluded that most patients who were using Coxibs before the withdrawal of Vioxx®, substituted Coxibs for COX-inhibitors, that are known for their possible gastro-intestinal side-effects. Recommendations for future research regarding NSAID use were also made, and included an investigation of the usage of Coxibs in different age groups, as well as the combination of NSAIDs with gastro-protective medicines in long-term use.
Thesis (M.Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2009.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "Non-steroidal anti-inflammatory Drug (NSAID)"

1

H, Stewart J., ed. Analgesic and NSAID-induced kidney disease. Oxford: Oxford University Press, 1993.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Jørgen, Rask Madsen, and Lauritsen Karsten, eds. Aspects of non-steroidal anti-inflammatory drug therapy. London: Baillière Tindall, 2001.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

T, Borda Ivan, and Koff Raymond S. 1939-, eds. NSAIDs: A profile of adverse effects. Philadelphia, Pa: Hanley & Belfus, 1992.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

1941-, Rainsford K. D., and Powanda M. C, eds. Safety and efficacy of non-prescription (OTC) analgesics and NSAIDs: Proceedings of the international conference held at the South San Francisco Conference Center, San Francisco, CA, USA on Monday 17th March 1997. Dordrecht: Kluwer, 1998.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

J, Lowe N., and Hensby C. N, eds. Nonsteroidal anti-inflammatory drugs. Basel: Karger, 1989.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Clinch, David. Peptic ulcer and its drug causation: The role of non-steroidal anti-inflammatory drugs. London: Croom Helm, 1986.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Robinson, Dwight R., and Fred E. Silverstein. Nonsteroidal anti-inflammatory drug-induced gastrointestinal damage: Current insights into patient management. Newton, MA: Cahners Pub. Co., 1988.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Ekberg, EwaCarin. Treatment of temporomandibular disorders of arthrogeneous origin: Controlled double-blind studies of non-steroidal anti-inflammatory drug and a stabilisation appliance. Malmo, Sweden: Department of Stomatognathic Physiology Centre for Oral Health Sciences, Lund University, 1998.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

F, Willkens Robert, and Dahl Stephen L, eds. Therapeutic controversies in the rheumatic diseases. Orlando: Grune & Stratton, 1987.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Kay, Brune, ed. Dipyrone: Recent investigations on its mode of action, pharmacokinetics, and clinical use : Berlin, October 24th, 1991. Basel: Birkhäuser Verlag, 1992.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "Non-steroidal anti-inflammatory Drug (NSAID)"

1

Day, Richard O. "Variability in Response to NSAID." In Non-steroidal Anti-Inflammatory Drugs Basis for Variability in Response, 15–19. Basel: Birkhäuser Basel, 1985. http://dx.doi.org/10.1007/978-3-0348-7720-6_1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Furst, Daniel E. "Significance of NSAID Serum to Response Relationships." In Non-steroidal Anti-Inflammatory Drugs Basis for Variability in Response, 141–49. Basel: Birkhäuser Basel, 1985. http://dx.doi.org/10.1007/978-3-0348-7720-6_17.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Grennan, D. M., L. Aarons, and R. Salisbury. "Problems with demonstrating NSAID concentration-response relationships." In Non-steroidal Anti-Inflammatory Drugs Basis for Variability in Response, 163–68. Basel: Birkhäuser Basel, 1985. http://dx.doi.org/10.1007/978-3-0348-7720-6_20.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

McGill, P. E. "NSAID — plasma concentration monitoring — optimizing treatment of R.A." In Non-steroidal Anti-Inflammatory Drugs Basis for Variability in Response, 157–61. Basel: Birkhäuser Basel, 1985. http://dx.doi.org/10.1007/978-3-0348-7720-6_19.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Bellamy, N. "Variance in NSAID studies: Contribution of Patient Variance." In Non-steroidal Anti-Inflammatory Drugs Basis for Variability in Response, 21–28. Basel: Birkhäuser Basel, 1985. http://dx.doi.org/10.1007/978-3-0348-7720-6_2.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Barnham, M., and A. W. Anderson. "Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)." In Streptococci and the Host, 145–47. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4899-1825-3_35.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Baldo, Brian A., and Nghia H. Pham. "Non-steroidal Anti-inflammatory Drugs." In Drug Allergy, 439–71. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-51740-3_9.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

O’Brien, William M. "Hepatitis due to non-steroidal anti-inflammatory drugs (NSAIDs)." In Side-Effects of Anti-Inflammatory Drugs 3, 211–22. Dordrecht: Springer Netherlands, 1992. http://dx.doi.org/10.1007/978-94-011-2982-4_26.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Kean, W. F., and D. Buxton. "Medico-Legal Issues of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)." In Side Effects of Anti-Inflammatory Drugs IV, 330–32. Dordrecht: Springer Netherlands, 1997. http://dx.doi.org/10.1007/978-94-011-5394-2_39.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Borchers, Angela. "Non-Steroidal Anti-Inflammatory Drug Intoxications." In Textbook of Small Animal Emergency Medicine, 856–61. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781119028994.ch133.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Non-steroidal anti-inflammatory Drug (NSAID)"

1

Kupryś-Lipińska, Izabela, Lucyna Mastalerz, Pawel Majak, Katarzyna Tyrak, Joanna Molinska, Mateusz Jonakowski, Zofia Kurmanowska, et al. "The effect of omalizumab on blood eosinophils count in patients with hypersensitivity to non-steroidal anti-inflammatory drugs (NSAID) compare to patients who tolerate NSAID–pilot study." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa1128.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Drummond Júnior, Délio Guerra, Tamires Rodrigues Toqueto, Rainally Sabrina Freire de Morais, Rodrigo Daniel Zanoni, and Igor Costa Santos. "Indications for anesthetics in the postoperative period of surgery in children." In III SEVEN INTERNATIONAL MULTIDISCIPLINARY CONGRESS. Seven Congress, 2023. http://dx.doi.org/10.56238/seveniiimulti2023-096.

Повний текст джерела
Анотація:
Introduction: Proper management of postoperative pain in children is of utmost importance to ensure patients' comfort and adequate recovery. Anesthetics play a key role in this context, providing effective analgesia and minimizing adverse effects associated with pain. Objectives: To analyze the indications of anesthetics in the postoperative period of surgeries in children, examining the available options, their mechanisms of action, the available scientific evidence and the clinical benefits. Theoretical Framework: The topics covered include the different types of anesthetics used in 4 axes: opioids, local anesthetics, non-steroidal anti-inflammatory drugs (NSAIDs) and adjuvant anesthetics. In addition, it deals with the specific indications for the use of each type of anesthetic, the appropriate doses and the possible side effects. Methodology: The literature search was conducted using the electronic databases PubMed, Scopus and Web of Science. The following English descriptors were used: "postoperative pain management", "children", "analgesics". The inclusion criteria adopted comprised original articles available in full text and written in English. Final Results: Opioids, such as morphine and fentanyl, are frequently used to control severe pain, but should be administered with caution due to possible side effects, such as respiratory depression and excessive sedation. Local anesthetics, such as bupivacaine and lidocaine, are widely used for regional blocks and local analgesia, reducing the need for systemic opioids. NSAIDs, such as ibuprofen and paracetamol, are effective and safe options for mild to moderate pain management with few side effects. Study results indicate that the choice of anesthetic in postoperative surgery in children should be based on individual patient characteristics, type of surgery, pain intensity, and safety profile of the drug.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Valle, Blanca L., Theresa D'Souza, Kevin G. Becker, William H. Wood, Robert P. Wersto, and Patrice J. Morin. "Abstract C96: The effect of non‐steroidal anti‐inflammatory drugs (NSAIDs) in ovarian cancer cells." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/1535-7163.targ-09-c96.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Cho, Dong Ha, Ki Kwang Oh, and Md Adnan. "Potential non-steroidal anti-inflammatory drugs (NSAIDs) and novel mechanism insights against COVID-19 through network pharmacology." In 6th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2020. http://dx.doi.org/10.3390/ecmc2020-07362.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Valle, Blanca L., Theresa D'Souza, Kevin G. Becker, William H. Wood, Robert P. Wersto, and Patrice J. Morin. "Abstract 4673: The anti-proliferative effects of non-steroidal anti-inflammatory drugs (NSAIDs) diclofenac and indomethacin in ovarian cancer cells." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-4673.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Basille, Damien, Reimar Wernich Thomsen, Morten Madsen, Pierre Duhaut, Claire Andrejak, Vincent Jounieaux, and Henrik Toft Sørensen. "Non-steroidal anti-inflammatory drug use and clinical outcomes of community-acquired pneumonia." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa2024.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Page, Andrew J., Katie Spencer, Matthew R. Mulvey, Barry JA Laird, and Michael I. Bennett. "P-75 Non-steroidal anti-inflammatory drugs (NSAIDs) in cancer pain: testing patient eligibility for recruitment to a clinical trial." In Accepted Oral and Poster Abstract Submissions, The Palliative Care Congress, Recovering, Rebounding, Reinventing, 24–25 March 2022, The Telford International Centre, Telford, Shropshire. British Medical Journal Publishing Group, 2022. http://dx.doi.org/10.1136/spcare-2022-scpsc.96.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Wan, Mei, Jiyuan Fang, Jiale Zhang, Zhi Hong, and Yong Du. "Terahertz Spectroscopy and Crystal Structure Analysis of Non-Steroidal Anti-Inflammatory Drug Ethenzamide Cocrystals." In 2022 47th International Conference on Infrared, Millimeter and Terahertz Waves (IRMMW-THz). IEEE, 2022. http://dx.doi.org/10.1109/irmmw-thz50927.2022.9895745.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Park, J., JO Kim, SR Jeon, HG Kim, TH Lee, JH Cho, BM Ko, JS Lee, and MS Lee. "REBLEEDING RATE AND RELATED RISK FACTORS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUG-INDUCED ENTEROPATHY." In ESGE Days 2018 accepted abstracts. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1637501.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Samain, Clementine, Gabriel Thabut, Jean-Francois Boitiaux, Stephanie Pham, Francois Senechal, and Bruno Philippe. "Influence of prior nonsteroidal anti-inflammatory steroidal drugs (NSAID) on the presentation and evolution of hospitalized community-acquired pneumonia." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa1837.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Non-steroidal anti-inflammatory Drug (NSAID)"

1

Davis, Brian. Non-Steroidal Anti-Inflammatory Drug Use in Collegiate Athletes. Portland State University Library, January 2000. http://dx.doi.org/10.15760/etd.2474.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Li, Xiao, GX Xu, FY Ling, ZH Yin, Y. Wei,, Y. Zhao, Xn Li, WC Qi, L. Zhao, and FR Liang. The dose-effect association between electroacupuncture sessions and its effect on chronic migraine: a protocol of a meta-regression of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2022. http://dx.doi.org/10.37766/inplasy2022.12.0085.

Повний текст джерела
Анотація:
Review question / Objective: We will use a meta-regression approach to verify the dose-effect relationship between the number of electroacupuncture sessions and its effects on migraine. Condition being studied: Migraine is recurrent and chronic, requiring long-term control, but the side effects caused by long-term use limit the use of pharmacotherapy, like non-steroidal anti-inflammatory drugs (NSAIDS), ergoamines and opioids. With fewer side effects and lower cost, acupuncture is becoming a more attractive option for migraine. Relevant studies have confirmed the clinical effects of electroacupuncture on migraine and its effects on intracranial blood flow velocity, functional brain imaging and neuroinflammation. However, uncertainty exists regarding the dose-effect between electroacupuncture and migraine. In recent years, inspired by the dose-effect researches in pharmacology and epidemiology, researches focusing on the dose-effect association between acupuncture and diseases has also begun to emerge. So in this protocol, we designed to use a meta-regression approach to explore the optimal electroacupuncture dose for migraine.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Chou, Roger, Jesse Wagner, Azrah Y. Ahmed, Ian Blazina, Erika Brodt, David I. Buckley, Tamara P. Cheney, et al. Treatments for Acute Pain: A Systematic Review. Agency for Healthcare Research and Quality (AHRQ), December 2020. http://dx.doi.org/10.23970/ahrqepccer240.

Повний текст джерела
Анотація:
Objectives. To evaluate the effectiveness and comparative effectiveness of opioid, nonopioid pharmacologic, and nonpharmacologic therapy in patients with specific types of acute pain, including effects on pain, function, quality of life, adverse events, and long-term use of opioids. Data sources. Electronic databases (Ovid® MEDLINE®, PsycINFO®, Embase®, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews) to August 2020, reference lists, and a Federal Register notice. Review methods. Using predefined criteria and dual review, we selected randomized controlled trials (RCTs) of outpatient therapies for eight acute pain conditions: low back pain, neck pain, other musculoskeletal pain, neuropathic pain, postoperative pain following discharge, dental pain (surgical or nonsurgical), pain due to kidney stones, and pain due to sickle cell disease. Meta-analyses were conducted on pharmacologic therapy for dental pain and kidney stone pain, and likelihood of repeat or rescue medication use and adverse events. The magnitude of effects was classified as small, moderate, or large using previously defined criteria, and strength of evidence was assessed. Results. One hundred eighty-three RCTs on the comparative effectiveness of therapies for acute pain were included. Opioid therapy was probably less effective than nonsteroidal anti-inflammatory drugs (NSAIDs) for surgical dental pain and kidney stones, and might be similarly effective as NSAIDs for low back pain. Opioids and NSAIDs were more effective than acetaminophen for surgical dental pain, but opioids were less effective than acetaminophen for kidney stone pain. For postoperative pain, opioids were associated with increased likelihood of repeat or rescue analgesic use, but effects on pain intensity were inconsistent. Being prescribed an opioid for acute low back pain or postoperative pain was associated with increased likelihood of use of opioids at long-term followup versus not being prescribed, based on observational studies. Heat therapy was probably effective for acute low back pain, spinal manipulation might be effective for acute back pain with radiculopathy, acupressure might be effective for acute musculoskeletal pain, an opioid might be effective for acute neuropathic pain, massage might be effective for some types of postoperative pain, and a cervical collar or exercise might be effective for acute neck pain with radiculopathy. Most studies had methodological limitations. Effect sizes were primarily small to moderate for pain, the most commonly evaluated outcome. Opioids were associated with increased risk of short-term adverse events versus NSAIDs or acetaminophen, including any adverse event, nausea, dizziness, and somnolence. Serious adverse events were uncommon for all interventions, but studies were not designed to assess risk of overdose, opioid use disorder, or long-term harms. Evidence on how benefits or harms varied in subgroups was lacking. Conclusions. Opioid therapy was associated with decreased or similar effectiveness as an NSAID for some acute pain conditions, but with increased risk of short-term adverse events. Evidence on nonpharmacological therapies was limited, but heat therapy, spinal manipulation, massage, acupuncture, acupressure, a cervical collar, and exercise were effective for specific acute pain conditions. Research is needed to determine the comparative effectiveness of therapies for sickle cell pain, acute neuropathic pain, neck pain, and management of postoperative pain following discharge; effects of therapies for acute pain on non-pain outcomes; effects of therapies on long-term outcomes, including long-term opioid use; and how benefits and harms of therapies vary in subgroups.
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "Non-steroidal anti-inflammatory Drug (NSAID)" для конкретних типів джерел:
Статті в журналах Дисертації Книги
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії